Supplementary Material for: The association between antiplatelet therapy and changes in intraplaque hemorrhage in patients with mild to moderate symptomatic carotid stenosis: a longitudinal MRI study

Introduction: Carotid atherosclerotic intraplaque hemorrhage (IPH) predicts stroke. Patients with a history of stroke are treated with antiplatelet agents to prevent secondary cardiovascular events. A positive association between previous antiplatelet use and IPH was reported in a cross-sectional analysis. We investigated changes in IPH over two years in patients who recently started versus those with continued antiplatelet use.
Methods: In the Plaque at Risk (PARISK) study, symptomatic patients with 0.05). No significant associations were found between new antiplatelet use and newly developed IPH at two years (odds ratio (OR)=1.0, 95% CI:0.1-7.4) or the progression of IPH (ipsilateral: OR=2.4, 95% CI:0.3-19.1; contralateral: OR=0.3, 95% CI:0.01-8.5).
Conclusion: Although the baseline association between IPH and previous antiplatelet therapy was confirmed in this larger cohort, the new onset of antiplatelet therapy after TIA/stroke was not associated with newly developed IPH or progression of IPH volume over the subsequent two years.

引言：颈动脉粥样硬化斑块内出血（IPH）是预测中风的指标。既往有中风病史的患者在接受抗血小板治疗以预防继发性心血管事件。一项横断面分析报告了既往抗血小板使用与IPH之间的正相关。本研究旨在探讨近期开始抗血小板治疗与持续抗血小板治疗的患者在两年内IPH变化情况。方法：在PARISK研究中，对有症状的患者进行了评估，其中颈动脉粥样硬化斑块面积≥0.05。未发现新开始抗血小板治疗与两年内新发IPH（优势比（OR）=1.0，95%置信区间：0.1-7.4）或IPH体积进展（同侧：OR=2.4，95%置信区间：0.3-19.1；对侧：OR=0.3，95%置信区间：0.01-8.5）之间存在显著关联。结论：尽管在本更大队列中证实了IPH与既往抗血小板治疗之间的基线关联，但TIA/中风后新开始抗血小板治疗与随后两年内新发IPH或IPH体积进展并无关联。